Xenon Xe 133 Gas as well as other radioactive drugs, must be handled with care and appropriate safety measures should be used to minimize radiation exposure to clinical personnel. Also, care should be taken to minimize radiation exposure to the patients consistent with proper patient management.

Exhaled Xenon Xe 133 Gas should be controlled in a manner that is in compliance with the appropriate regulations of the government agency authorized to license the use of radionuclides.


Radiopharmaceuticals should be used only by physicians who are qualified by training and experience in the safe use and handling of radionuclides.

ADVERSE REACTIONS

Adverse reactions specifically attributable to Xenon Xe 133 Gas have not been reported.

USE IN SPECIFIC POPULATIONS

Pregnancy Category C. Xenon Xe 133 Gas should be given to a pregnant woman only if clearly needed.

Breastfeeding: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Xenon Xe 133 Gas is administered to a nursing woman.

Pediatric Use: Safety and effectiveness in pediatric patients have not been established.


About Curium
Curium is a world-class nuclear medicine solutions provider with more than a century of industry experience. Formed by the union of IBA Molecular and Mallinckrodt Nuclear Medicine LLC, Curium is the largest vertically integrated radiopharmaceutical product manufacturer in the industry. With manufacturing facilities across Europe and the United States, Curium supports over 14 million patients around the word with SPECT, PET, and therapeutic radiopharmaceuticals to provide potentially life-saving diagnostic solutions. The Curium brand name is inspired by the work of radiation researchers Marie and Pierre Curie and emphasizes a focus on nuclear medicine.

Back to HCB News

Molecular Imaging Homepage